AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9812183
Drug: High-dose standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose standard heparin 300 U/kg as an intravenous bolus
Trial: 2693117
Drug: 4-methylpyrazole (4‐MP)
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-methylpyrazole (4‐MP) at 10 mg.kg‐1
Trial: 2693117
Drug: 4-methylpyrazole (4‐MP)
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-methylpyrazole (4‐MP) at 20 mg.kg‐1
Trial: 2693117
Drug: 4-methylpyrazole (4‐MP)
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-methylpyrazole (4‐MP) at 100 mg.kg‐1
Trial: 28651249
Drug: TRO40303 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRO40303 (intravenous bolus)
Trial: 25604090
Drug: Social media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social media intervention for low-income adolescent mothers; delivered via a web-based application over 6 weeks, includes daily behavioral challenges, text message reminders, discussion forums, and website information.
Trial: 19543563
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to a dual reuptake inhibitor
Trial: 19543563
Drug: Augmentation strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation strategies
Trial: 19543563
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy as a switch or augmentation strategy
Trial: 19543563
Drug: Antidepressants in
RxNorm normalized name: Other antidepressants in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants in augmentation
Trial: 17465354
Drug: Ulna implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulna implants with surrounding bone blocks
Trial: 17465354
Drug: Conventional sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sinus augmentation with particulated autogenous bone grafts
Trial: 15649285
Drug: ISO (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISO (100 mg) tablets
Trial: 15649285
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (P group) containing vitamins C (25 mg) and E (5 mg)
Trial: 9533351
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical treatment with oral agents and exogenous insulin injection
Trial: 3391875
Drug: Erythromycin acistrate
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin acistrate (EA) 400 mg
Trial: 3391875
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (EB) enterotablet A 500 mg
Trial: 3391875
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (EB) enterotablet B 500 mg
Trial: 3391875
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (EB) enterotablet A 500 mg (multiple dosing)
Trial: 3391875
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (EB) enterotablet B 500 mg (multiple dosing)
Trial: 3391875
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 + 800 mg
Trial: 29363287
Drug: Lorcaserin 10
RxNorm normalized name: lorcaserin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10 mg twice daily (LOR BID)
Trial: 29363287
Drug: Lorcaserin 10
RxNorm normalized name: lorcaserin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10 mg twice daily (LOR BID) + Phentermine 15 mg once daily (LOR BID + PHEN QD)
Trial: 29363287
Drug: Lorcaserin 10
RxNorm normalized name: lorcaserin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10 mg twice daily (LOR BID) + Phentermine 15 mg twice daily (LOR BID + PHEN BID)
Trial: 27353237
Drug: Temporary, transcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary, transcutaneous, pharmaceutical SGB with lidocaine
Trial: 17825472
Drug: Skin closure
RxNorm normalized name: dressings, skin closures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin closure by staples with closure of subcutaneous space
Trial: 17825472
Drug: Skin closure
RxNorm normalized name: dressings, skin closures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin closure by staples with non-closure of subcutaneous space
Trial: 17825472
Drug: Intracutaneous suture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous suture with closure of subcutaneous space
Trial: 17825472
Drug: Intracutaneous suture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous suture with non-closure of subcutaneous space
Trial: 16389216
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (18, 36, 54, or 72 mg once daily)
Trial: 12930332
Drug: High-power 50-ms
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-power 50-ms 1064 Nd:YAG laser treatment
Trial: 11293738
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mcg/kg) administered intravenously within 1 hour of surgery and every 12 hours thereafter, switched to enteral captopril (3 mg/kg/day) every 8 hours when tolerating feeds.
Trial: 11293738
Drug: No angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No angiotensin converting enzyme inhibitors administered (Control group).
Trial: 8433561
Drug: Insulin with
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin with dextrose infusion
Trial: 8433561
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion with insulin and glucose
Trial: 3303247
Drug: Non-administered group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-administered group
Trial: 30479287
Drug: Anesthetic cream
RxNorm normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic cream (2.5% lidocaine/2.5% prilocaine)
Trial: 27683967
Drug: Interpersonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal therapy for complicated grief (CG) treatment
Trial: 26577943
Drug: Home group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home group (oral amoxicillin treatment at home)
Trial: 26577943
Drug: Hospital group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital group (oral amoxicillin treatment in hospital for first 48 hours)
Trial: 19034749
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 to 120 mg QD, titrated based on response, with 90 mg QD as an intermediate dose)
Trial: 12667566
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy after VT
Trial: 12667566
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy after VF
Trial: 11108507
Drug: Anticonvulsant levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant levels
Trial: 9183334
Drug: rt-PA and
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rt-PA and heparin therapy
Trial: 30007160
Drug: Guanfacine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine 0.1 mg
Trial: 7669311
Drug: Guanfacine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine 0.5 mg
Trial: 30007160
Drug: Guanfacine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (both doses)
Trial: 22573644
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus pravastatin (10-20 mg/d)
Trial: 16442264
Drug: Combined technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined technique using nitrous oxide/oxygen and intravenous Midazolam
Trial: 9431825
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion (ethanol administered by i.v. infusion)
Trial: 29729702
Drug: Kidney Flaccidity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney Flaccidity Compound (KFC) for 1.5 months
Trial: 29729702
Drug: Kidney Flaccidity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney Flaccidity Compound (KFC) for 3 months
Trial: 29729702
Drug: Kidney Flaccidity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney Flaccidity Compound (KFC)
Trial: 23885616
Drug: Elongated needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elongated needle treatment
Trial: 20629511
Drug: Genomic approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomic approaches to treatment response including detection of gene rearrangements, DNA copy-number aberrations, single-nucleotide polymorphisms, epigenetic changes, and differential gene-expression patterns.
Trial: 20629511
Drug: Genomic approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomic approaches to treatment response
Trial: 1376839
Drug: Modified-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release formulation of isradipine (Im) at 5 mg once daily
Trial: 1376839
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of isradipine (Is) at 2.5 mg twice daily
Trial: 1376839
Drug: Modified-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release formulation of isradipine (Im)
Trial: 1376839
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of isradipine (Is)
Trial: 2864027
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control treatment
Trial: 31726876
Drug: G-estimation method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-estimation method for treatment on the outcome (physical activity)
Trial: 31726876
Drug: G-estimation method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-estimation method
Trial: 28793896
Drug: MEDI8968 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI8968 300 mg subcutaneously every 4 weeks (600 mg intravenous loading dose) for 52 weeks
Trial: 28793896
Drug: MEDI8968 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI8968 300 mg
Trial: 21426232
Drug: Cinnarizine 25
RxNorm normalized name: cinnarizine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 25 mg every 12 hours for 6 months (n=50)
Trial: 18279183
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus sub-antimicrobial dose of doxycycline
Trial: 17262127
Drug: Carisolv gel
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carisolv gel + SRP
Trial: 17262127
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel + SRP
Trial: 12527536
Drug: Functional adaptation
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional adaptation skills training (FAST) group therapy program (24 sessions)
Trial: 10770538
Drug: Zidovudine (ZDV;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150 mg twice per day)
Trial: 10770538
Drug: Zidovudine (ZDV;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150 mg twice per day) plus indinavir (IND; 800 mg q8h)
Trial: 26902950
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 3-month formulation (PP3M)
Trial: 23953322
Drug: Ketamine (0.227
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.227 mg/kg for ED50; 0.283 mg/kg for ED95)
Trial: 20560900
Drug: Sertindole 12
RxNorm normalized name: sertindole 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole 12 mg
Trial: 20560900
Drug: Sertindole 20
RxNorm normalized name: sertindole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole 20 mg
Trial: 20560900
Drug: Sertindole 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole 24 mg
Trial: 20560900
Drug: Haloperidol 8
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 8 mg
Trial: 20560900
Drug: Haloperidol 16
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 16 mg
Trial: 17869975
Drug: Caspofungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (50 mg/d after a 70-mg loading dose)
Trial: 17869975
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.6-1.0 mg/kg per day)
Trial: 15491237
Drug: ACASI survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACASI survey self‐administered through an Internet browser using a touchscreen
Trial: 11505696
Drug: Soft type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft type margarine (30 g total per day, 15 g twice a day)
Trial: 11505696
Drug: Butter (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butter (30 g total per day, 15 g twice a day)
Trial: 9752402
Drug: Laparoscopic repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic repair (L group)
Trial: 31650328
Drug: High-fibre intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fibre intake (39 g/day)
Trial: 31650328
Drug: Low-fibre intake
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fibre intake (18 g/day)
Trial: 23862170
Drug: 14-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day triple therapy (subgroup)
Trial: 23862170
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy (subgroup)
Trial: 17934721
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of nicotine delivered via nasal spray
Trial: 17071438
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 2 g/day
Trial: 17071438
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 10 mg twice-daily
Trial: 10740110
Drug: Fenspiride (Pneumorel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenspiride (Pneumorel 80mg) plus antibiotic therapy (Amoxicillin 500mg plus clavulanic acid 125, 3 tablets/day)
Trial: 10740110
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus antibiotic therapy (Amoxicillin 500mg plus clavulanic acid 125, 3 tablets/day)
Trial: 9200635
Drug: Levomethadyl acetate
RxNorm normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levomethadyl acetate hydrochloride (LAAM) high-dose condition (100/100/140 mg)
Trial: 9200635
Drug: Levomethadyl acetate
RxNorm normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levomethadyl acetate hydrochloride (LAAM) medium-dose condition (50/50/70 mg)
Trial: 9200635
Drug: Levomethadyl acetate
RxNorm normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levomethadyl acetate hydrochloride (LAAM) low-dose condition (25/25/35 mg)
Trial: 8261875
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of methadone
Trial: 9283506
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of methadone
Trial: 8261875
Drug: methadone-free treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methadone-free treatment
Trial: 31215440
Drug: QbTest added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QbTest added to medication management
Trial: 29843676
Drug: Intake of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intake of typical antipsychotics
Trial: 25312554
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of insulin (group 1)
Trial: 25312554
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of insulin glargine (group 2)
Trial: 25312554
Drug: Insulin dosage
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dosage during 6-month follow-up
Trial: 8089358
Drug: Fibrel implant
RxNorm normalized name: triticum (wheat fibre)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrel implant
Trial: 4603999
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg prednisone, daily for a week
Trial: 22855914
Drug: UHV-HPMC (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UHV-HPMC (4 g)
Trial: 22855914
Drug: Psyllium fiber
RxNorm normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium fiber (4 g)
Trial: 18331577
Drug: No-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment group (NTG)
Trial: 12907528
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation plus inhaled ipratropium bromide
Trial: 27527344
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion threshold (eligible for transfusion if post-operative haemoglobin < 7.5 g/dl)
Trial: 27527344
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion threshold (eligible for transfusion immediately after randomisation if post-operative haemoglobin < 9 g/dl)
Trial: 17030104
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) - estrogen plus progesterone
Trial: 15793193
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (OGTT) at baseline and after approximately 2 years
Trial: 15793193
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in insulin sensitivity related to weight change
Trial: 15793193
Drug: Fasting glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose, insulin, and C-peptide
Trial: 7792438
Drug: rhDNase 0.6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNase 0.6, 2.5, 10 mg
Trial: 7792438
Drug: rhDNase 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNase 2.5 mg, once or twice daily
Trial: 2235167
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (including crossover)
Trial: 369049
Drug: Supervised oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised oral hygiene action with amine fluoride-containing agents Silca and Elmex fluid
Trial: 25596660
Drug: Chemoradiotherapy (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (three cycles of cisplatin 100 mg/m(2))
Trial: 25596660
Drug: Panitumumab plus
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab plus chemoradiotherapy (three cycles of intravenous panitumumab 9.0 mg/kg every 3 weeks plus cisplatin 75 mg/m(2))
Trial: 23131530
Drug: Hydrochlorothiazide 1
RxNorm normalized name: hydrochlorothiazide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 1 mg/kg/day as morning dose
Trial: 22379918
Drug: FFP 5423+417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFP 5423+417 ml and crystalloids 11048+458 ml (1:2 ratio)